netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
10.01.03  Expand sub section  Drugs which suppress the rheumatic disease process
10.01.03  Expand sub section  Gold
10.01.03  Expand sub section  Penicillamine
10.01.03  Expand sub section  Antimalarials
10.01.03  Expand sub section  Drugs affecting the immune response to top
Cytotoxic Drug Azathioprine
View adult BNF View SPC online View childrens BNF
Formulary
Amber
  • See section 8.2.1
 
Link  County Durham and Darlington Shared Care Guideline: Azathioprine
Link  South Tyneside & Sunderland APC Shared Care Guideline - Azathioprine in Rheumatology
Link  Tees Valley Shared Care Guideline: Azathioprine
 
Ciclosporin
View adult BNF View SPC online View childrens BNF
Formulary
Amber
  • See section 8.2.2
 
Link  County Durham and Darlington Shared Care Guideline: Ciclosporin
Link  Tees Valley Shared Care Guideline: Ciclosporin
 
Leflunomide
View adult BNF View SPC online View childrens BNF
Formulary
Amber
 
Link  County Durham and Darlington Shared Care Guideline: Leflunomide
Link  South Tyneside & Sunderland APC Shared Care Guideline - Leflunomide in Rheumatology
Link  Tees Valley Shared Care Guideline: Leflunomide
 
Cytotoxic Drug Methotrexate
(Rheumatology)
View adult BNF View SPC online View childrens BNF
Formulary
Amber
 
Link  County Durham and Darlington Shared Care Guideline: Methotrexate
Link  South Tyneside & Sunderland APC Shared Care Guideline - Methotrexate in Rheumatology
Link  Tees Valley Shared Care Guideline: Methotrexate
 
Mycophenolate
View adult BNF View SPC online View childrens BNF
Formulary
Amber
 
Link  County Durham and Darlington Shared Care Guideline: Mycophenolate mofetil and mycophenolic acid
Link  South Tyneside & Sunderland APC Shared Care Guideline - Mycophenolate in Rheumatology
Link  Tees Valley Shared Care Guideline: Mycophenolate mofetil
 
10.01.03  Expand sub section  Cytokine modulators
10.01.03  Expand sub section  Sulfasalazine
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GPís prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances. For all RED drugs automatically added to the formulary in response to a positive NICE TA: Prescribers need to ensure that local Trust new drug governance procedures and pharmacy processes are followed before any prescribing.  

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patientís GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by a specialist (hospital or GP with an extended role https://www.rcgp.org.uk/gpwer), but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case. Provision of additional information, or an information leaflet, may be appropriate in some cases to facilitate continuing treatment by GPs.  

Green

Drugs where prescribing by GPs is appropriate. Can be initiated and prescribed in all care settings, and if appropriate, discontinued without recourse to secondary care.  

Black

NOT APPROVED: Drugs that have been considered by NTAG or the NENC ICB Medicines Subcommittee (or other approved body) and are not approved for prescribing within the North East and North Cumbria.   

Brown

UNDER REVIEW: drugs whose current formulary status or RAG status is currently under review.  

Not Recomended

NOT REVIEWED: Drugs that haven not been reviewed yet. This usually means that an application is in progress. These drugs are not normally considered appropriate for prescribing in the North East and North Cumbria until such time that a decision is taken on their formulary status.  

netFormulary